Extended release granisetron: Review of pharmacologic considerations and clinical role in the perioperative setting

Anh L Ngo; Vwaire Orhurhu; Ivan Urits; Edwin O Delfin; Medha Sharma; Mark R Jones; Omar Viswanath; Richard D Urman

doi:10.4103/sja.SJA_817_18

Extended release granisetron: Review of pharmacologic considerations and clinical role in the perioperative setting

Saudi J Anaesth. 2019 Jul-Sep;13(3):231-236. doi: 10.4103/sja.SJA_817_18.

Authors

Anh L Ngo¹, Vwaire Orhurhu¹, Ivan Urits¹, Edwin O Delfin¹, Medha Sharma², Mark R Jones¹, Omar Viswanath^{3

4

5}, Richard D Urman⁶

Affiliations

¹ Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.
² University of Pennsylvania, Philadelphia, PA, USA.
³ Valley Anesthesiology and Pain Consultants, Phoenix, AZ, USA.
⁴ University of Arizona College of Medicine-Phoenix, Department of Anesthesiology, Phoenix, AZ, USA.
⁵ Creighton University School of Medicine, Department of Anesthesiology, Omaha, NE, USA.
⁶ Brigham and Women's Hospital, Department of Anesthesiology, Perioperative, and Pain Medicine, Harvard Medical School, Boston, MA, USA.

Abstract

In this review, we evaluate recent literature on use of ER granisetron in clinical practice as compared with current antiemetics and describe its potential uses for perioperative PONV prophylaxis and treatment. Recent literature was evaluated on ER granisetron use compared with currently used antiemetic agents ondansetron, droperidol, metoclopramide, promethazine, and dexamethasone with a focus on procedural anti-emesis. Though promising great effect, application of extended release granisetron to clinical use may be limited by it's increased relative cost.

Keywords: 5-HT3 antagonists; anti-emetics; pharmacotherapy; post-operative nausea and vomiting.

Publication types

Review